SCHEMBL19968759

SCHEMBL19968759

Cc1ccccc1-c1nc(N)ccc1Cl

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BACE1 P56817 2/20 0.47
▸ CTSD P07339 1/20 0.47
▸ ADORA2A P29274 1/20 0.46
▸ PLA2G7 Q13093 1/20 0.42
▸ DPP4 P27487 3/20 0.40
▸ LMNA P02545 1/20 0.40
▸ NOS3 P29474 1/20 0.39
▸ NOS1 P29475 1/20 0.39
▸ NOS2 P35228 1/20 0.39
▸ HSP90AA1 P07900 1/20 0.38
▸ EPHA4 P54764 1/20 0.38
▸ HEXA P06865 1/20 0.37
▸ HEXB P07686 1/20 0.37
▸ ACHE P22303 1/20 0.37
▸ MEN1 O00255 2/20 0.37
▸ NPC1 O15118 2/20 0.37
▸ RAB9A P51151 2/20 0.37
▸ KMT2A Q03164 2/20 0.37
▸ DCUN1D1 Q96GG9 1/20 0.37
▸ MAPT P10636 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29464888 1.00 BACE1 (0.47) BACE1CTSDADORA2APLA2G7DPP4
SCHEMBL19968794 0.81 NOS3 (0.42) BACE1CTSDNOS3NOS1NOS2
SCHEMBL19925120 0.77 ABL1 (0.46) BACE1CTSDPLA2G7NOS3NOS1
SCHEMBL29464929 0.77 ABL1 (0.46) BACE1CTSDPLA2G7NOS3NOS1
SCHEMBL23770590 0.77 ADORA2A (0.35) BACE1CTSDADORA2APLA2G7DPP4
SCHEMBL19968754 0.75 HSD11B1 (0.38) BACE1CTSDADORA2ALMNAHPGD
SCHEMBL19968786 0.75 BACE1 (0.44) BACE1CTSDADORA2ADPP4LMNA
SCHEMBL23770688 0.74 DPP4 (0.33) BACE1CTSDADORA2ADPP4
SCHEMBL23770777 0.74 ADORA2A (0.33) BACE1CTSDADORA2ADPP4EPHA4
SCHEMBL29464947 0.74 NPC1 (0.41) BACE1DPP4LMNAMEN1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109641873-B N- (pyridin-2-yl) pyridine-sulfonamide derivatives and their use for the treatment of disease 诺华股份有限公司 2022-03-18 — — CN disclosed
EP-3504194-B1 N-(PYRIDIN-2-YL)PYRIDINE-SULFONAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE NOVARTIS AG (CH) 2021-08-18 — — EP disclosed
US-11066369-B2 N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease NOVARTIS AG (CH) 2021-07-20 — — US disclosed
US-10450273-B2 N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease NOVARTIS AG (CH) 2019-10-22 — — US disclosed
US-20180072673-A1 N-(pyridin-2-yl)pyridine-sulfonamide Derivatives and their Use in the Treatment of Disease NOVARTIS AG (CH) 2018-03-15 — — US disclosed
US-20180072673-A1 N-(pyridin-2-yl)pyridine-sulfonamide Derivatives and their Use in the Treatment of Disease NOVARTIS AG (CH) 2018-03-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11066369-B2 N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease CFTR, P2RY1, P2RX5 BACE1 3951/4885CTSD 3310/4885ADORA2A 1072/4885
US-20180072673-A1 N-(pyridin-2-yl)pyridine-sulfonamide Derivatives and their Use in the Treatment of Disease CFTR, P2RY1, P2RX5 BACE1 3951/4885CTSD 3310/4885ADORA2A 1072/4885
US-10450273-B2 N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease CFTR, P2RY1, P2RX5 BACE1 3951/4885CTSD 3310/4885ADORA2A 1072/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback